A Phase I/II, Randomized, Double-blind, Comparator-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of TLC590 for Postsurgical Pain Management Following Inguinal Hernia Repair
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 18 Dec 2018
At a glance
- Drugs Ropivacaine (Primary) ; Ropivacaine
- Indications Postoperative pain
- Focus Adverse reactions; First in man
- Sponsors Taiwan Liposome Company
- 18 Dec 2019 According to a Taiwan Liposome Company media release, topline data is expected in the first quarter of 2019.
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting, according to a Taiwan Liposome Company media release.
- 20 Aug 2018 Planned End Date changed from 1 Jan 2019 to 5 Jan 2019.